Q1 2019 Cytokinetics Inc Earnings Call Transcript
Good afternoon and welcome, ladies and gentlemen, to the Cytokinetics First Quarter 2019 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in listen-only mode. At the request of the company, we will open the call for question and answers after the presentation. I will now turn the call over to Diane Weiser, Cytokinetics' Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, everyone and thank you for joining us today. Robert Blum, our President and Chief Executive Officer, will kick-off the call with introductory comments about the current state of our business. Then Fady Malik, our EVP of Research and Development, will provide updates on our cardiac muscle program, including the Phase 3 development of omecamtiv mecarbil, our cardiac myosin activator, and the Phase 1 development of AMG 594, a cardiac troponin activator, both under our collaboration with Amgen, as
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |